Contents 目 錄 | 2 | Corporate Information | 公司資料 | | --- | --- | --- | | 5 | Core Financial and Operational Data | 核心財務及運營數據 | | 7 | Financial Summary | 財務摘要 | | 8 | Chairman's Statement | 董事長致辭 | | 15 | Management Discussion and Analysis | 管理層討論及分析 | | 55 | Directors and Senior Management | 董事及高級管理層 | | 61 | Directors' Report | 董事會報告 | | 100 | Corporate Governance Report | 企業管治報告 | | 117 | Environmental, Social and Governance Report | 環境、社會及管治報告 | | 180 | Independent Auditor's Report | 獨立核數師報告 | | 191 | Con ...

2024年度中康控股（2361.HK）交出了一份稳中有进的成绩单：全年收入达4.04亿元人民币，同比增长1.9%；净利润达1.12亿元，同比增长10.8%。 在医药健康产业面临AI重塑生产力的背景下，这份成绩不仅展现了公司在加速推进AI战略下的强劲执行力，也印证了其在垂直医疗健康场景中的深度布局 和技术壁垒的高附加值。 中康控股的成功并非偶然，而是其在数据积累、技术创新、生态化布局和政策红利多重因素叠加下的必然结果。 1、双料加持：东方科技崛起与提振医疗背景下的价值新机遇 2024年，全球资本市场呈现"东升西落"格局——以中国为核心的东方科技资产重估浪潮迭起，叠加国内提振消费以及支持医疗健康产业发展等相关政策的密 集落地，兼具科技硬实力与医疗场景优势的龙头企业迎来价值重估的历史性窗口。 在这一大背景下，作为战略布局深度契合两大市场主线的中康控股，其有望在双重机遇中获得新的价值增长点。 （来源：富途行情） 科技资产重估视角下，在全球产业链重构背景下，中国科技企业正从"场景应用者"向"标准制定者"跃迁。 中康作为国内医疗健康数据科技领域的领军者，公司在研发上持续投入，特别是在AI、大数据与医疗场景融合等前沿科技领 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部分內容而產生 或因依賴該等內容而引致的任何損失承擔任何責任。 Sinohealth Holdings Limited 中康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2361） 截 至 2024 年 12 月 31 日止年度之 年度業績公告 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至12月31日止年度 | | | | | 2024年 | 2023年 | 同比變動 | | | 人民幣 | 人民幣 | | | | （千元） | （千元） | % | | 收入 | 403,728 | 396,194 | 1.9% | | 智慧決策雲 | 254,495 | 269,164 | -5.4% | | 智慧零售雲 | 88,875 | 71,564 | 24.2% | | 智慧醫療雲 | 38,254 | 41,393 | -7.6% | | 智慧健康管理雲 | 22,104 | 14,073 | 57.1% ...

Sinohealth HIdg 中康控股 中 康 控 股 有 限 公 司 Sinohealth Holdings Limited (Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限公司 ) Stock Code 股份代號: 2361 2024 INTERIM REPORT 中期報告 .alial SAAS Contents 目 錄 2 公司資料 | --- | --- | --- | |-------|-------------------------------------------------------------------------------------------------------|-------------------------------------------| | | | | | | Corporate Information | | | 5 | Core Financial and Operational Data | 核心財務及運營數據 | | 6 | Financial S ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部分內容而產生 或因依賴該等內容而引致的任何損失承擔任何責任。 Sinohealth Holdings Limited 中康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2361） 截 至 2024 年 6 月 30 日 止 六個月中期之業績公告 | --- | --- | --- | --- | |----------------------------------------------------|-----------------------|-------------------|----------------| | | | | | | 財務摘要 | | | | | | 截至 6 月 30 | 日止六個月 | | | | 2024 年 | 2023 年 | | | | （未經審核） | （未經審核） | 同比變動 | | | 人民幣（千元） | 人民幣（千元） | | | 收入 | 159,531 | 144,950 | 10.1% | | ...

Financial Performance - For the year ended December 31, 2023, the revenue reached RMB 396,194,000, representing an increase of 11.1% compared to RMB 356,668,000 in 2022[15]. - Gross profit for 2023 was RMB 223,472,000, up 40.5% from RMB 159,108,000 in 2022[15]. - Net profit increased significantly to RMB 100,940,000 in 2023, compared to RMB 54,213,000 in 2022, marking an increase of 85.5%[15]. - The Group's operating revenue increased to RMB396.2 million, representing a year-on-year increase of 11.1%[38]. - Gross profit rose to approximately RMB223.5 million, reflecting a year-on-year increase of approximately 40.5%, with gross profit margin increasing from 44.6% in FY2022 to 56.4%[38]. - Profit for the year surged by 86.2% year-on-year to RMB100.9 million, with net profit margin increasing by 10.3 percentage points year-on-year to 25.5%[38]. - The Group's profit for the year increased by approximately 86.2%, from approximately RMB54.2 million in 2022 to approximately RMB100.9 million in 2023[124][129]. - Other income and gains increased by approximately 9.5%, from approximately RMB37.7 million in 2022 to approximately RMB41.3 million in 2023, mainly due to an increase in bank interest income[115][118]. Asset Management - Non-current assets rose to RMB 188,477,000 in 2023, a substantial increase from RMB 94,285,000 in 2022[15]. - Current assets decreased to RMB 609,264,000 in 2023 from RMB 702,188,000 in 2022, reflecting a decline of 13.3%[15]. - The total equity of the company was RMB 700,454,000 in 2023, slightly up from RMB 693,236,000 in 2022[15]. - Cash and cash equivalents decreased by approximately 69.7%, amounting to approximately RMB123.9 million as of 31 December 2023, primarily due to the placement of idle funds in time deposits[132][137]. - The gearing ratio was approximately 13.9% as of 31 December 2023, a slight decrease from approximately 14.9% as of 31 December 2022[134]. - The Group had no short-term or long-term bank borrowings as of December 31, 2023, apart from lease liabilities totaling approximately RMB14.2 million[133][138]. Market and Industry Insights - The healthcare industry in China is projected to grow from RMB 9 trillion in 2022 to RMB 16 trillion by 2030, with the serious medical industry reaching RMB 9.6 trillion and consumer medical industry reaching RMB 6.4 trillion[22]. - The serious medical industry is expected to have a CAGR of 5.8%, while the consumer medical industry is projected to grow at a CAGR of 9.8%[22]. - The healthcare industry is expected to experience explosive growth in health big data and digital products, reshaping the industry profile in China[16]. - The rapid growth of the data-driven economy is expected to increase demands for data insights and digital services in the healthcare industry[22]. Technology and Innovation - The company is focusing on developing three core technologies: big data, artificial intelligence, and cloud computing to enhance healthcare industry efficiency[16]. - The Group provided more than 30 SaaS products and professional insight services, enhancing data governance capabilities and enabling efficient decision-making for medical product suppliers[18]. - The Smart Medical Cloud achieved an operating revenue of approximately RMB41.4 million in the financial year, representing a year-on-year increase of approximately 12% compared to FY2022[66]. - The self-developed Lingsu System achieved a market data response time of T+3, positioning the company at a leading level in the industry[46]. - The AI-MDT system will continue to innovate and expand its functions, providing comprehensive health management services to physical examination institutions and hospitals[99]. Customer and Market Expansion - The number of corporate customers reached 1,288, an increase of 44.6% from 891 in the same period of FY2022, with a repurchase sales rate of leading customers at 95.7%[34]. - The number of cooperative pharmacies increased by 22% year-on-year, with over 100,000 pharmacy stores established for SIC products, maintaining a rapid growth trend[50]. - The Smart Decision Cloud service had 804 corporate customers as of December 31, 2023, representing a year-on-year increase of approximately 39.6%, with a repurchase sales rate of 88.9%[41]. - The Group's medical retail cooperative network reached 1,735 partnering medical retail enterprises and 129,555 partnering pharmacy stores as of December 31, 2023, representing a year-on-year increase of 16% and 22%, respectively[75]. Corporate Governance and Management - The company has a strong governance structure with multiple committees including Audit and Remuneration Committees[180]. - The management team includes professionals with extensive backgrounds in finance and management, enhancing strategic decision-making capabilities[175]. - The company emphasizes the importance of independent judgment in management oversight through its board members[184][185]. - The Group has developed a comprehensive vocational training system and a sound remuneration and promotion system to attract and retain talent[152]. Strategic Initiatives - The Group aims to build three development curves: To B, To C, and To R, focusing on data-driven digital services for the healthcare industry[27]. - The strategy includes enhancing technical innovation and establishing long-term cooperative relationships with customers[27]. - The Group plans to leverage its core advantages in data governance and application technology to accelerate the development of a patient-centered digital health management system[87]. - The Group will focus on three major development directions: expanding corporate business (To B), enhancing customer-end health services (To C), and creating a digital empowerment platform for biomedical R&D (To R)[89].

Financial Performance - Revenue increased by 11.1% year-on-year to RMB 396.2 million in 2023[2][4] - Gross profit grew by 40.5% to RMB 223.5 million, with gross margin rising from 44.6% to 56.4%[4] - Net profit surged by 86.2% to RMB 100.9 million[2][4] - Revenue increased by 11.1% from RMB 356.7 million in 2022 to RMB 396.2 million in 2023, driven by growth in the Smart Decision Cloud business[23] - Cost of sales decreased by 12.6% from RMB 197.6 million in 2022 to RMB 172.7 million in 2023 due to improved operational efficiency[24] - Gross profit increased by 40.5% from RMB 159.1 million in 2022 to RMB 223.5 million in 2023, with gross margin rising from 44.6% to 56.4%[25] - Other income and gains increased by 9.5% from RMB 37.7 million in 2022 to RMB 41.3 million in 2023, primarily due to higher bank interest income[26] - Profit before tax surged by 103.3% from RMB 54.5 million in 2022 to RMB 110.7 million in 2023, mainly due to increased gross profit[30] - Net profit for the year rose by 86.2% from RMB 54.2 million in 2022 to RMB 100.9 million in 2023[32] - Revenue for 2023 increased to RMB 396.194 million, up from RMB 356.668 million in 2022, with gross profit rising to RMB 223.472 million from RMB 159.108 million[44] - Net profit for 2023 was RMB 100.940 million, compared to RMB 54.213 million in 2022[44] - Total revenue for 2023 reached RMB 396.194 million, a 11.1% increase from RMB 356.668 million in 2022[54] - Pre-tax profit for 2023 increased to RMB 110,741 thousand, up from RMB 54,474 thousand in 2022, reflecting significant growth[68] - The actual tax rate for 2023 was 8.9%, compared to 0.5% in 2022, indicating a substantial increase in tax expenses[68] Business Segments Performance - Revenue from the Smart Decision Cloud segment grew by 47.3% to RMB 269.2 million, with 804 enterprise clients and an 88.9% repurchase rate[2][7] - The Smart Retail Cloud segment revenue decreased by 43.4% to RMB 71.6 million[2] - The Smart Medical Cloud segment revenue increased by 12.0% to RMB 41.4 million[2] - The Smart Health Management Cloud segment revenue grew by 34.6% to RMB 14.1 million[2] - Smart Decision Cloud revenue surged by 47.3% to RMB 269.164 million in 2023[56] - Data Insight Solutions revenue decreased to RMB 195.741 million in 2023 from RMB 225.262 million in 2022, a 13.1% decline[56] - Data-Driven Publishing & Events revenue increased by 57.9% to RMB 143.616 million in 2023[56] - SaaS product revenue grew by 40.4% to RMB 56.837 million in 2023[56] - Revenue from services transferred at a point in time increased to RMB 169.924 million in 2023, up 28.7% from 2022[56] Client and Market Expansion - The number of enterprise-level clients increased by 44.6% to 1,288, with a 95.7% repurchase rate among top pharmaceutical and medical device clients[4] - Signed but not yet executed contracts totaled over 500, amounting to approximately RMB 154.1 million, a 79.2% increase year-on-year[4] - The company's SIC products have established partnerships with over 100,000 pharmacy stores as of December 31, 2023, representing a 22% year-over-year growth[8] - The company's smart retail cloud SaaS products have helped 622 enterprise-level clients, a 51.7% increase compared to the previous fiscal year, with an overall repurchase rate of 84.6%[9] - The company's data network covers over 120,000 pharmacy stores across 30 provinces and 349 cities, with total sales from partnered pharmacies exceeding 160 billion yuan in 2023, accounting for approximately 30% of the national total sales[12] - 80% of the partnered pharmacy stores provide real-time data, and over 80% of the stores offer real-time order-level data[12] - The number of partnered pharmacy stores increased by 22% year-over-year to 129,555 as of December 31, 2023[14] - The number of pharmacy employees increased by 25% year-over-year to 239,000 as of December 31, 2023[14] Technology and Innovation - The AI-MDT system, which integrates expertise from over 300 specialists across 16 disciplines, covers 31 disease categories, 1,770 diseases, and 801 single indicators, and has a daily processing capacity of over 30,000 health reports[10] - The company's data processing platform, Sinohealth-Engine, has a machine auto-cleaning rate of over 97% and an accuracy rate exceeding 99%, with the fastest response time reaching T+1[14] - The company has established 38 standardized and structured master databases covering various health industry sectors, including pharmaceutical retail, regulatory, medical, and life sciences[14] - The company's "Tiangong-1" commercial data intelligence platform and "Zhumuniao" smart health management platform enhance data value mining capabilities[14] - AI-MDT refers to the customized health management solution provided by the company for physical examination users, utilizing AI technology for multidisciplinary analysis and evaluation of user reports[86] - The company's smart decision cloud product, Lingtong, helps customers efficiently formulate marketing strategies, improve marketing effectiveness, and track results in real-time[87] - The company's smart retail cloud product, SIC, provides comprehensive services including business management, membership management, and intelligent marketing for pharmacies[88] - The company's smart retail cloud product, Yilingtong, offers customized data-driven marketing solutions, enhancing marketing effectiveness and tracking results in real-time[89] Financial Position and Capital Management - Cash and cash equivalents decreased by 69.7% to RMB 123.9 million as of December 31, 2023, due to the placement of idle funds into fixed deposits[34] - The company has no short-term or long-term bank borrowings, with only RMB 14.2 million in lease liabilities[36] - The asset-liability ratio decreased to 13.9% as of December 31, 2023, from 14.9% in 2022[37] - Capital expenditures decreased by 18.5% to RMB 3.4 million in 2023, primarily for equipment, software acquisition, and leasehold improvements[39] - The company had no significant contingent liabilities, guarantees, or major litigation as of December 31, 2023[40] - Total non-current assets increased to RMB 188.477 million in 2023 from RMB 94.285 million in 2022, driven by growth in property, plant, and equipment, and fixed deposits[45] - Total current assets decreased to RMB 609.264 million in 2023 from RMB 702.188 million in 2022, primarily due to a reduction in cash and cash equivalents[45] - Total equity increased slightly to RMB 700.454 million in 2023 from RMB 693.236 million in 2022[46] - The company's shares were listed on the Hong Kong Stock Exchange on July 12, 2022[49] - The company issued 75,000,000 shares at a price of HKD 5.36 per share during its IPO on July 12, 2022, raising approximately USD 47.47 million (equivalent to approximately RMB 319.40 million) after deducting listing expenses[75] - A capital increase of 370,000,000 shares was issued at par value on the listing date, with RMB 24.90 million allocated from the share premium account[75] - The company repurchased 20,585,500 shares in 2022 for a total consideration of approximately HKD 112.87 million (equivalent to approximately RMB 101.12 million) under the share award scheme[76] - In 2023, the company repurchased 16,210,500 shares for a total consideration of approximately HKD 86.46 million (equivalent to approximately RMB 77.98 million) under the share award scheme[76] - The board proposed a final dividend of HKD 0.0725 per share for the year ended December 31, 2023, payable on September 25, 2024[78] - The proposed final dividend per share increased to 7.25 HK cents in 2023 from 3.98 HK cents in 2022, indicating improved shareholder returns[68] - The weighted average number of ordinary shares used for basic earnings per share calculation increased to 426,125,312 in 2023 from 410,666,838 in 2022[68] Corporate Governance and Compliance - The company has adopted the principles and provisions of the Corporate Governance Code, except for the separation of the roles of Chairman and CEO[80] - The company has established an audit committee consisting of three independent non-executive directors, with Mr. Wei Bin as the chairman[84] - The annual report containing all information required by the listing rules will be sent to shareholders and published on the company's website[85] - The company will suspend share registration from June 14, 2024, to June 19, 2024, for the 2024 Annual General Meeting[79] - Share registration will also be suspended from June 26, 2024, to June 27, 2024, to determine shareholders eligible for the proposed final dividend[79] Employee and Operational Metrics - The company's total number of full-time employees increased to 759 in 2023, up from 680 in 2022, with employee costs rising by 1.4% to RMB 148.0 million[41] - Employee distribution by function: 43% in solutions and products, 31% in R&D, 16% in sales and marketing, and 10% in general and administrative roles[42] - The company acquired a 50.6% stake in Guangzhou Zhonghui Medical Technology for RMB 12,238,921 on February 5, 2024[43] Industry and Market Trends - China's digital economy reached 50.2 trillion yuan in 2022, accounting for 41.5% of GDP, with a nominal growth rate of 10.3% year-on-year[16] - The "Data Element X" three-year action plan (2024-2026) aims for an average annual growth rate of over 20% in the data industry and a doubling of data transaction scale by 2026[16] - The company's health industry platform, including the "Xipu Conference," has become a leading industry event in China, with over 100,000 professionals in the pharmaceutical retail, medical device, and healthcare sectors[15] - The company successfully held the first "Traditional Chinese Medicine Ecological Conference" in December 2023, extending its industry platform resources to the upstream and downstream of the traditional Chinese medicine industry chain[15] Future Development and Strategy - The company will focus on three main development directions: expanding To B business, developing To C health services, and building a To R digital empowerment platform for biopharmaceutical R&D[17] - The company plans to enhance its Smart Decision Cloud by introducing more B2C and O2O data sources, developing predictive models, and providing data visualization SaaS tools[18] - The Smart Retail Cloud will help pharmaceutical retail enterprises improve staff management, member engagement, and sales efficiency through digital transformation[19] - The company's AI-MDT system will provide digital solutions for体检机构 and hospitals, aiming to serve 870 million体检人次 annually in China[20] Financial Risks and Credit Management - Trade receivables for 2023 amounted to RMB 111,351 thousand, up from RMB 92,028 thousand in 2022, showing an increase in credit sales[69] - The impairment loss on trade receivables increased to RMB 23,530 thousand in 2023 from RMB 6,322 thousand in 2022, due to higher overdue balances[70] - The expected credit loss rate for trade receivables over 1 year increased to 78.9% in 2023 from 65.9% in 2022, indicating higher credit risk[73] - Trade payables decreased to RMB 13,109 thousand in 2023 from RMB 14,665 thousand in 2022, reflecting a reduction in outstanding payments[73] - The company's credit terms with customers generally range from 7 to 120 days, with strict controls over outstanding receivables[69] Tax and Regulatory Environment - Tax expenses in Mainland China for 2023 were RMB 11,114 thousand, a sharp increase from RMB 1,880 thousand in 2022[65] - Certain subsidiaries in Mainland China were recognized as small and micro enterprises, benefiting from a preferential tax rate of 5%[66] Shareholder and Investor Relations - The company's issued and fully paid ordinary shares remained unchanged at 451,770,000 shares in both 2023 and 2022[74] - The proposed final dividend per share increased to 7.25 HK cents in 2023 from 3.98 HK cents in 2022, indicating improved shareholder returns[68] - The weighted average number of ordinary shares used for basic earnings per share calculation increased to 426,125,312 in 2023 from 410,666,838 in 2022[68] - The board proposed a final dividend of HKD 0.0725 per share for the year ended December 31, 2023, payable on September 25, 2024[78] - The company will suspend share registration from June 14, 2024, to June 19, 2024, for the 2024 Annual General Meeting[79] - Share registration will also be suspended from June 26, 2024, to June 27, 2024, to determine shareholders eligible for the proposed final dividend[79]

Sinohealth HIdg 中康控股 中 康 控 股 有 限 公 司 Sinohealth Holdings Limited (Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限公司 ) Stock Code 股份代號: 2361 2023 INTERIM REPORT 中期報告 | --- | --- | --- | |-------|--------------------------------------------------------------------------------------------|-----------------------------------| | | | | | | | | | | Contents | | | 目 | 錄 | | | 2 | Corporate Information | 公司資料 | | 6 | Core Financial and Operational Data | 核心財務及運營數據 | | 7 | Financial Summary ...

[5 -> 32] 大家好 欢迎参加中康控股2023年中报业绩交流会目前所有参会者均处于静音状态下面开始播报免责声明本次会议仅服务于邀请参会的广大投资者会议音频及文字记录的内容仅供参会者内部使用不得公开发布中康控股未授权任何媒体转发本次会议相关内容未经允许和授权的转载转发均属侵权 [32 -> 62] 中康控股将保留追究其法律责任的权利中康控股不承担因转载转发而产生的任何损失和责任市场有风险投资需谨慎提醒广大投资者谨慎做出投资决策在会议开始前我们提示各位投资者在主讲嘉宾发言结束后将留有提问时间首先介绍今天参与本次交流会的公司领导他们是公司CFO兼联席公司秘书易旭辉女士 [62 -> 91] 公司IR负责人万川先生下面有请公司领导发言谢谢各位投资者下午好感谢参与参加我们中央控股在2023年的一个中期的业绩交流会中央控股是 [92 -> 121] 立足于基于大数据人工智能和云计算对生命科学领域的一个效率提升提供数字化一体化解决方案的一家公司我们今天的分享分为三个部分第一部分是我们的经营今年上半年的经营亮点第二点的话是我们对整个行业趋势做一个研判第三是我们会说一下我们未来的一个经营计划 [130 -> 155] 我 ...

B_table indent_4.5 mm N_table indent_4 mm 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 不 會 就 因 本 公 告 全 部 或 任 何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Sinohealth Holdings Limited 中 康 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2361） | --- | --- | --- | --- | --- | --- | |----------------|------------------|---------------|------------------|----------|----------| | | | | | | | | 主要財務業績 | | | | | | | | | 截 至 月 | 止六個月 | | | | | 2023 年 | 6 30 佔總收入 | 2022 年 | 佔總收入 | | | | （未經審核） | 百分比 | （未經審核） ...